HYPREVENTION
16.12.2015 18:34:07 CET | Business Wire | Press release
After obtaining the CE marking for the medical device Y-STRUT ® in August 2015, HYPREVENTION recorded its first sales in France and signed its first distribution agreement in Belgium. To continue its business development in Europe and in many emerging countries. HYPREVENTION raised € 750,000 end of 2015. Investors comprised Expanso CAPITAL, a subsidiary of the Caisse d'Epargne Aquitaine Poitou Charente, as well as the Be Angels, Business Angels Switzerland and Cercle des Investisseurs de Genève.
About Y-STRUT
®
:
The implant Y-STRUT®
,
developed by HYPREVENTION, aims at preserving the autonomy and quality
of life of the patients who are at risk of hip fracture. Hip fracture is
a major public health problem which frequently causes dependency and
associated expenses.
Y-STRUT®
is used in two clinical
indications. In trauma
, for the biomechanical reinforcement of
the proximal femur in patients having incurred a low energy trochanteric
fracture on the other side, and in oncology
, for percutaneous
internal reinforcement of impending pathological fractures of the
proximal femur.
About HYPREVENTION:
HYPREVENTION was created in 2010 by
Cécile Vienney (CEO) and 3 orthopaedic surgeons. HYPREVENTION is a
French company that develops, manufactures and markets innovative
implantable medical devices to address major public health issues.
HYPREVENTION was supported in its early development by the French public
actors such as BPI France and the Regional Council of Aquitaine.
Thanks
to the recent fund raising, HYPREVENTION can now further develop its
sales team and implement the opportunities it identified in Europe,
South America and the Middle East. HYPREVENTION can now not only pursue
its scientific agenda through clinical trials focused on patient’s
benefit, but also the planned health economy studies necessary to
support the hip fracture prevention approach as a goal to avoid health
costs.
About Expanso CAPITAL:
Expanso CAPITAL is the capital
investment subsidiary close to the Caisse d'Epargne Aquitaine
Poitou-Charentes, dedicated exclusively to assist corporate clients of
the bank, regardless of their activities and their maturity stage, and
this with "tickets " of € 50,000 to € 300,000.
About the Caisse d'Epargne Aquitaine Poitou Charentes:
Caisse
d'Epargne Aquitaine Poitou Charente is a cooperative regional bank owned
by its 334,300 member clients with which it shares its democratic
values, territorial roots and solidarity. Covering the 9 departments of
Aquitaine and Poitou-Charentes regions, CEAPC enjoys optimum territorial
coverage with 3 administrative sites, 10 business centres, sales offices
and 376 e-agency’s. Its 2800 employees are serving 2 million customers,
individuals, professionals, companies and regional market makers. A
committed bank, CEAPC is developing an ambitious CSR policy based on
strong convictions and relevant actions around the following themes:
customer relationships, human resources, environment, governance,
regional social and economic life.
About Be Angels:
Be Angels is the active business angel
network in the Walloon Region and the Brussels-Capital Region. With 15
years of experience, the network organizes a monthly event in which four
companies seeking financing, usually in start-up phase, present their
project to its member investors. Business angels are willing not only to
invest, but also to support project promoters in accordance with their
needs. Be Angels allows its members to invest according to their wealth,
time availability, and investment objectives.
About BAS :
BAS (Business Angels Switzerland), the largest
business angels club in the country, showed interest for Hyprevention
from the outset. BAS supports start-up companies through capital
financing, expertise sharing and know-how, as well as personal contacts
and access to its network; it is with this mind-set that its support
forHyprevention materialised. BAS members invest their own time and
money, and financed more than 80 enterprises within the framework of the
club.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151216006003/en/
Contact:
HYPREVENTION:
Cecile Vienney,
+33 (0)5 57 10 28 52
contact@hyprevention.com
or
Expanso
CAPITAL:
Jean-Luc Minet
jean-luc.minet@ceapc.caisse-epargne.fr
or
Be
Angels:
Claire Munck
clmunck@beangels.be
or
BAS
:
Caroline Gueissaz
Caroline.Gueissaz@businessangels.ch
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom